PuraMed BioScience, Inc. Appoints Former Quigley Corporation COO, Charles A. Phillips, to the Board of Directors

PuraMed BioScience, Inc. Appoints Former Quigley Corporation COO, Charles A.
Phillips, to the Board of Directors

SCHOFIELD, Wis., Dec. 12, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience Inc.
(OTCBB:PMBS) is pleased to announce the appointment of Charles A. Phillips to
the Board of Directors. Phillips began his pharmaceutical career in 1989 when
he helped create, via an IPO, The Quigley Corporation, which he was, until the
company's take over in 2009, the COO and Board member.

Quigley Corporation was responsible for one of the most successful launches of
an over the counter product, Cold-Eeze™ in 1992. From the product's start,
Phillips was responsible for its formulation development, manufacturing
refinements, further clinical testing, production ramp-up, packaging,
distribution, marketing, as well as sales and advertising. During his tenure,
the Company took the product to national distribution in all major drug
chains, mass-market stores and it became the number one Pharmacist recommended
product in the cough/cold category.

Russ Mitchell CEO of PuraMed BioScience, said, "I have known Charles Phillips
for many years and his track record of successfully developing and launching
new products makes him an excellent addition to the board. I believe he will
bring a fresh perspective and a wealth of contacts and will be in a position
to add value from the beginning."

Mitchell had the opportunity to work directly with Phillips in the past when
he was serving as the Master Broker for The Quigley Corp. during the launch of
Cold-Eeze. Together they were instrumental in placing Cold-Eeze into
approximately 50,000 retail outlets across the United States.

About the PuraMed BioScience, Inc.:

PuraMed BioScience, Inc. engages in the research, development and marketing of
non-prescription medicinal and healthcare products. PuraMed has completed a
double blind placebo clinical trial for its leading product, LipiGesic®M, a
sublingual acute treatment for the relief from migraine headaches, which was
published in the top-tier medical journal, Headache. Please see the following
link to view the abstract of that study.
http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract.
LipiGesic®M has national distribution and is available nationwide in some of
the largest chain drug stores in the United States.In addition to
LipiGesic®M, the Company also has plans to launch LipiGesic®H for tension-type
headaches as well as LipiGesic®PM which provides a remedy for insomnia and
other sleep disorders.

Forward-Looking Statements: 

This news release contains forward-looking statements regarding PuraMed
BioScience and its future business plans, which statements involve known and
unknown risks and uncertainties. Such risks and uncertainties may cause actual
results and future achievements of PuraMed BioScience to be materially
different than those implied by these forward-looking statements. PuraMed
BioScience has and undertakes no obligation to provide public updates and
revisions to these forward-looking statements to reflect any changes in its
expectations of future events.

CONTACT: PuraMed BioScience, Inc.
         Russell Mitchell, Chairman and CEO
         715-359-6373
         rmitchell@PuramedBioScience.com
         www.PuramedBioScience.com
        
         Investor Relations:
         Investor Awareness, Inc.
         Tony Schor or James Foy
         847-945-2222
         www.investorawareness.com
 
Press spacebar to pause and continue. Press esc to stop.